AMLX · Amylyx Pharmaceuticals Inc
United States · RS rating 97 · As of 2026-11-03
| Price | 29.20 USD |
|---|---|
| 1-day change | +4.1% |
| RS rating (overall / 1M / 3M / 12M) | 97 / 72 / 93 / 95 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 43 / 39 / 60 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +18.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +26.4% |
| Market cap (USD) | $1.9B |